Training | 2009.10.01
Dyadic International Completes FDA GRAS Notification Process for C1-Derived Cellulase Enzyme
JUPITER, Fla.--(BUSINESS WIRE)--Dyadic International, Inc. (Pink Sheets:DYAI) (“Dyadic”) today announced that it has received acknowledgement from the U.S. Food and Drug Administration (“FDA”) that it has no questions at this time regarding Dyadic’s conclusion that the cellulase enzyme preparation derived from a genetically modified strain of its patented and proprietary C1 organism is generally recognized as safe (“GRAS”) under the intended conditions o
For more information, please visit
http://www.businesswire.com/news/home/20091001005213/en
Follow us on
📊 Most Viewed News
- • The complete guide to making your product international - The Nex... (15,533)
- • Colaboração 2.0: Breaking Down the Language Barrier - Business ... (12,028)
- • A Start-Up Bets on Human Translators Over Machines - New York Tim... (11,529)
- • Immigrants 'should learn English' - Politics.co.uk (11,193)
- • How OpenStack gets translated - opensource.com (11,035)
- • easyJet Chooses TransPerfect for Pan-European Translation - Busin... (10,933)
- • Para-Plus Translations Honored by Philadelphia Business Journal .... (10,365)
- • Google Adds Customized Translations for Website Owners - PC Magaz... (10,257)